Program

Saturday, September 27 | Sunday, September 28 | Monday, September 29

(Program as of August 2014)

Friday, September 26

11:00 am  Registration is Open
            (Viger Foyer)

1:30–6:00 pm  Poster Set up
              (Viger Hall)

1:30 pm  Ballroom is Open
          (All sessions to be held in Ballroom)

3:00–3:10 pm  Introductory Remarks

3:10–4:00 pm  Keynote Address
              Kenneth Fearon, MD, MBBch. Hons.
              Professor of Surgical Oncology
              University of Edinburgh
              United Kingdom

Session 1
Diagnostics and Biomarkers in Cancer Cachexia
(Chair: Daniel Marks, MD, PhD)

4:15–4:45 pm  Body Composition and Prognostication in Cancer
              Vickie Baracos, PhD
              Professor and Alberta Cancer Foundation Chair in Palliative Medicine
              Department of Oncology
              University of Alberta
              Edmonton Alberta, Canada

Cancer Cachexia
Cancer cachexia is characterized as a multifactorial syndrome defined by an ongoing loss of adipose and skeletal muscle mass that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Current data indicate that more than half of all cancer patients show evidence of the cachexia syndrome, leading to substantial impairment of respiratory muscle function and contributing to poor quality of life and decreased survival.
Myostatin as a Marker of Cachexia in Gastric Cancer
Maurizio Muscaritoli, PhD
Professor Department of Clinical Medicine Sapienza, University of Rome
Rome, Italy

Cutting Edge Science in Cancer Cachexia
(5 min teaser presentations from posters)

 Role of Activin A in Human Cancer Cachexia (ACTICA study)
Jean Paul Thissen, PhD (Brussels, Belgium)

Human Cancer Cachexia Pathways: Implications of Muscle Ageing?
Carson Jacobi, PhD (Novartis, Basel, Switzerland)

Prehabilitation vs Rehabilitation: A Randomized Control Trial in Patients Undergoing Colorectal Resection for Cancer
Rashami Awasthi (Concordia University, Montreal, Canada)

NEO1940: A Novel Cannabinoid Receptor Agonist with Reduced Brain Exposure as a Multimodal Supportive Care Therapy in Cancer Patients with Anorexia and Weight Loss
Sultan Ahmad, PhD (NEOMED Institute, Montréal, Canada)

Cachexia Evolution in Renal Cell Carcinoma Patients and its Relation with Cardiac Ejection Fraction Evaluated by MUGA Scan
Seyyed Mohammad Reza Kazemi-Bajestani (University of Alberta, Alberta, Canada)

Welcoming Reception
(Salon Maisonuneuve ABC – 36th floor)

Poster Viewing (Viger Hall)
Coffee & dessert (Viger Foyer)

Saturday, September 27

6:30-8:00 am  Breakfast
(Salon Maisonuneuve ABC – 36th floor)

Session 2
Mechanisms of Muscle Wasting in Cancer Cachexia:
Part I
(Chair: Teresa Zimmers, PhD)

8:00-8:30 am  The Role of p38beta MAPK in Cachexia
Yi-Ping Li, PhD
Associate Professor
Department of Integrative Biology and Pharmacology
8:30-9:00 am  Uncovering IL-6-independent mechanisms involved in STAT3-induced Cachexia
Imed Gallouzi, PhD
Professor
Biochemistry Department & Goodman Cancer Center
McGill University
Montreal, Quebec, Canada

9:00-9:15 am  BMP Axis in Experimental Cancer Cachexia
Robert Sartori, PhD
Venetian Institute of Molecular Medicine
Padova, Italy

9:15-9:30 am  Exploring New Targets within the TGFβ Signaling Network as Interventions for Cachexia
Paul Gregorevic, PhD
Laboratory Head
Baker IDI Heart and Diabetes Institute
Melbourne, Australia

9:30-9:45 am  Myofilament protein content and muscle function in cancer patients
Michael Toth, PhD
Department of Medicine
University of Vermont College of Medicine
Burlington, Vermont, USA

9:45-10:15 am  Coffee Break
(Viger Foyer)

10:15-10:45 am  Myostatin Function in Cancer Cachexia
Mridula Sharma, PhD
Associate Professor
Department of Biochemistry, National University of Singapore
Singapore

10:45-11:15 am  Cytokine Regulation of Muscle Wasting in Cachexia
Josep Argilés, PhD
Professor
University of Barcelona, Department of Biochemistry and Molecular Biology
Barcelona, Spain

11:15-11:30 am  Role of the USP19 deubiquitylating enzyme in muscle wasting and myogenesis
Simon S. Wing, MD
Professor
McGill University
Montreal, Quebec, Canada

11:30-12:00 pm  Cutting Edge Science in Cancer Cachexia
(5 min teaser presentations from posters)

**Persistent C/EBPβ Expression in Muscle Satellite Cells Contributes to the Pathogenesis of Cancer Cachexia**
Nadine Wiper-Bergeron, PhD (University of Ottawa, Ottawa, Canada)

**Inhibition of FoxO Prevents Cancer-Induced Diaphragm Atrophy and Inhibits Cardiac Pathology**
Andrew Judge, PhD (University of Florida, Gainesville, USA)

**What is the impact of AMPK activation on cytokine-induced muscle atrophy?**
Derek Hall (McGill University, Montreal, Canada)

**Inhibition of JAK/STAT3 Pathway with Ruxolitinib and Tofacitinib Does Not Block Skeletal Muscle Atrophy in C-26 Cancer Cachexia Model**
Tianshun Xu, PhD (GlaxoSmithKline, Durham, USA)

12:00-1:30 pm  **Lunch**
*(Salon Maisonneuve ABC – 36th floor)*

**Session 3**
**Cachexia Promoters from Outside the Myofiber**
*(Chair: Maurizio Muscaritoli, PhD)*

1:30-2:00 pm  **Neuroendocrine influences in Cachexia**
Daniel Marks, MD, PhD
Professor, Pediatric Endocrinology
Credit Union for Kids Professor in Pediatric Research
Oregon Health & Science University
Portland, Oregon, USA

2:00-2:30 pm  **The Role of the Muscle Stem Cell Niche in Regulating Regenerative Myogenesis**
Michael Rudnicki, OC, PhD, FRSC
Professor, Department of Medicine, University of Ottawa
Senior Scientist & Director Regenerative Medicine Program
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada

2:30-2:45 pm  **Tumor-derived GM-CSF Enhances Cancer-Associated Cachexia by Promoting Increased Adipocyte Lipolysis**
Aaron Laine, MD, PhD
Resident Radiation Oncology
UT Southwestern Medical Center
Dallas, Texas, USA

2:45-3:00 pm  **Cancer-Associated Cachexia: A switch from White to Brown Fat due to systemic inflammation leads to organ wasting**
Erwin Wagner, PhD
Professor
BBVA Foundation-CNIO Cancer Cell Biology Program
Madrid, Spain

3:00-3:15 pm  **Muscle Wasting and Impaired Myogenesis in Cachexia**
Paola Costelli, PhD
Professor,
Department of Clinical and Biological Science
University of Torino
Torino, Italy

3:15-3:45 pm  **Coffee Break**
*(Viger Foyer)*

3:45-4:15 pm  **SOCS3 is a bi-functional buffer of muscle growth and wasting**
Teresa Zimmers, PhD
Associate Professor,
Department of Surgery
IU Simon Cancer Center
Indiana University, School of Medicine
Indianapolis, Indiana, USA

4:15-4:45 pm  **Cachexia and the Role of the Muscle Microenvironment**
Denis Guttridge, PhD
Professor, Department of Molecular Virology, Immunology and Medical Genetics
The Ohio State University
Columbus, Ohio, USA

4:45-5:00 pm  **Cancer derived MIC-1/GDF15 induced starvation leads to Cachexia**
Samuel Breit, PhD
Professor
St Vincent's Hospital
Sydney, Australia

5:00-7:00 pm  **Poster Viewing (Judging)**
*(Viger Hall)*

7:45 pm  **Gala Dinner – Café Caf Conc’ Theatre**

*A Tribute to Neil MacDonald, MD and Special Presentation*  
*"Palliative Rehabilitation Program Improves Patient Functioning”*
Research Consultant
Bruyere Research Institute
Ottawa, Ontario, Canada

---

**Sunday, September 28**

6:30-8:00 am  **Breakfast**
*(Salon Maisonneuve ABC – 36th floor)*
Session 4
Mechanisms of Muscle Wasting in Cancer Cachexia: Part II
(Chair: Josep Argilés, PhD)

8:00-8:30 am  Ghrelin action in Cachexia
Andrea Graziani, PhD
Professor
Department of Translational Medicine
University of Piemonte Orientale
Novara, Italy

8:30-9:00 am  Signaling Pathways that Regulate Skeletal Muscle Atrophy and Hypertrophy
David Glass, MD
Novartis Institutes for Biomedical Research
Cambridge, Massachusetts, USA

9:00-9:30 am  Stress, inflammation and cachexia: role of physical activity
Dario Coletti, PhD
Assistant Professor
University Pierre et Marie Curie Paris 06
Paris, France

9:30-10:00 am  Thermogenesis and Altered lipid Metabolism in Cancer Cachexia
Graham Robertson, PhD
Senior Scientist
Tumorkine Group, The Kinghorn Cancer Centre Garvan Institute of Medical Research
Sydney, Australia

10:00-10:30 am  Announce Poster Winners; Coffee Break
(Viger Foyer)

10:30-10:45 am  TGF-β Mediates Muscle Weakness in Bone Metastases via Oxidation-Induced Calcium Leak
David L. Wanig, PhD
Assistant Research Professor
Indiana University Indianapolis,
Indiana, USA

10:45-11:00 am  T Cell Function in Diabetes and Cancer-Associated Cachexia
Joanna Davies, PhD
President and CEO
San Diego Biomedical Research Institute
San Diego, California, USA

11:00-11:30 am  IL-6 and Mitochondrial Dysfunction in Cachexia
James Carson, PhD
Professor
Department of Exercise Science
11:30-12:00 pm  **Molecular Signatures of Cancer Cachexia**  
Michel Tremblay, PhD  
Professor  
Department of Biochemistry / Goodman Cancer Center  
McGill University  
Montreal, Quebec, Canada

12:00-1:30 pm  **Lunch & Poster Pick up**  
*(Salon Maisonneuve ABC – 36th floor)*

### Session 5  
**Pre-Clinical to Clinical Studies**  
*(Chair: Vickie Baracos, PhD)*

1:30-2:00 pm  **Metabolic Rearrangement in Cancer Cachexia**  
Marion Couch, MD, PhD  
Professor, Chair OHNS Department  
Indiana University School of Medicine  
Indianapolis, Indiana, USA

2:00-2:30 pm  **Malignant Inflammation and its Role in Disease Progression and HPA Mediated Cancer Symptoms**  
Michael Stecher MD  
Medical Director  
XBiotech USA  
Austin, Texas, USA

2:30-3:00 pm  **Emerging Approaches to Treating Muscle Atrophy and Weakness**  
Mohamed El Mouelhi, MD, PhD, FACP  
Executive Director  
Translational Medicine,  
Musculoskeletal Novartis Institutes for Biomedical Research East Hanover, NJ, USA

3:00-3:15 pm  **HDAC Inhibition as a Therapeutic Strategy for Cancer Cachexia**  
Ching-Shih Chen, PhD  
Professor of Medicinal Chemistry  
College of Pharmacy and Comprehensive Cancer Center  
Ohio State University  
Columbus, Ohio, USA  
Institute of Biological Chemistry, Academia Sinica  
Taipei, Taiwan

3:15-3:45 pm  **Coffee Break**  
*(Viger Foyer)*

3:45-4:15 pm  **Targeting GDF15 with the inhibitory antibody AV-380 for the treatment of Cancer Cachexia**  
Lorena Lerner, PhD
Director
AVEO Oncology Inc.
Cambridge, Massachusetts, USA

4:15-4:30 pm  **Next Generation Sequencing of the Muscle and Fat Transcriptome in Patients with Cancer Cachexia Reveals Novel Mechanisms**
Amal H.I. Al Haddad, RN, BSN, MSHRM
PhD candidate - Cancer Biology Tract, Prof. Thomas E. Adrian Lab
Department of Physiology, College of Medicine
United Arab Emirates University
Al Ain, United Arab Emirates

4:30-4:45 pm  **Baseline Characteristics of Anamorelin Phase III Clinical Trial program (ROMANA), a novel Treatment for Anorexia-Cachexia in Non-Small Cell Lung Cancer (NSCLC) Patients**
Speaker for Helsinn

4:45-5:15 pm  **Ghrelin Therapy in Cancer Cachexia**
Jose M. Garcia, MD, PhD
Assistant Professor
Departments of Medicine and Molecular and Cell Biology
Baylor College of Medicine
Houston, Texas, USA

5:15pm  **Closing Remarks**